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ABSTRACT  
 
Background: Multiple sclerosis (MS) associated optic neuritis (MSON) causes atrophy of the 
inner retinal layers, which can be quantified by optical coherence tomography (OCT). It has 
been suggested that the Inter-Eye Percentage Difference (IEPD) of atrophy may be of 
diagnostic value in MSON. 
Methods: Prospective, longitudinal study in MS patients and healthy controls (HC). Spectral-
domain OCT of both eyes was performed, followed by automated retinal layer segmentation 
for the peripapillary retinal nerve fibre layer (pRNFL) and macular ganglion cell and inner 
plexiform layer (mGCIPL). Receiver Operator Characteristics Curves were plotted and the 
area under the curve (AUC) was calculated for group comparisons of the IEPD of the pRNFL 
and mGCIPL at baseline and 2 year follow-up. 
Results: There were 39 patients with bilateral MSON, 62 with unilateral MSON, 106 without 
MSON and 63 HC. Diagnostic accuracy (AUC) of the IEPD was 0.73-0.86 for pRNFL and 
0.75-0.94 for mGCIPL. The diagnostic sensitivity of the mGCIPL IEPD was 70% with a 
specificity of 97% for distinguishing unilateral MSON from HC at baseline. For the 
comparison of bilateral MSON with HC sensitivity was 86% with a specificity of 97%. 
Validation at 2 year follow up demonstrated sensitivity/specificity levels of 71%/97% 
(unilateral vs. HC) and  83%/97% (bilateral vs. HC). 
Conclusion: The IEPD of the pRNFL and more so the IEPD of the mGCIPL is an useful 
diagnostic measure for MSON. The IEPD is a dimensionless unit and may therefore 
contribute to overcome device and proprietary segmentation algorithm limitations.  
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INTRODUCTION 
The intimate relationship between optic neuritis (ON) and multiple sclerosis (MS) has long 
been recognised [1]. In fact, one of the most frequent clinically isolated syndromes  remains 
MS associated ON (MSON) [2]. The diagnosis for both conditions has been clinical [3; 4] and 
in the case of MS is based on finding evidence for dissemination in space (DIS) and 
dissemination in time (DIT) [5]. With the increasing recognition of the diagnostic sensitivity 
of MRI for DIS and DIT the need for clinical evidence has declined in the past two decades 
[6-8].  
There are cases however, either in clinical or research setting, in which there is a need to 
establish the presence of a previous (subclinical) episode of MSON but can be challenging. 
Clinically recommended [9; 10], the art of using an ophthalmoscope in practice has declined 
with emergence of new diagnostic techniques such as optical coherence tomography (OCT). 
In recognition of this development it was proposed to use a 20% inter-eye percentage 
difference (IEPD) of the peripapillary retinal nerve fibre layer (pRNFL) as a diagnostic 
criterion for MSON [10]. There are several advantages to a dimensionless variable such as the 
IEPD, one of which is that it is less likely that differences between devices and segmentation 
algorithms will matter. Because of class III evidence only for recommended consensus of a 
20% IEPD cut-off of the pRNFL on OCT this study aimed to define optimised cut-off ranges 
for the IEPD of the pRNFL and combined ganglion cell and inner plexiform layer (mGCIPL) 
for making a diagnosis of MSON. 
 
METHODS 
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This study was approved by the Medical Ethical Committees of the VU University Medical 
Center in Amsterdam, the Netherlands and is in accordance with the 1964 Declaration of 
Helsinki. Written informed consent was obtained from all subjects before study inclusion. 
 
Study design and patient population 
Patients with MS [8] and healthy control subjects (HC) were enrolled from the VU University 
Medical Center Amsterdam (VUmc).   
All subjects underwent clinical and OCT assessments at baseline and were retested after 24 
months. The assessment of MSON was based on medical history and always preceded the 
OCT measurement, making sure that the physician who established the diagnosis of MSON 
did not have the OCT data available at the time of assessment.  Disease duration was defined 
as the time from the first MS symptoms. The expanded disability status scale (EDSS) was 
obtained by a certified examiner. As potential swelling of the pRNFL during the acute stages 
of MSON may confound OCT measurements, patients were excluded if they had experienced 
symptomatic MSON three months prior to either OCT measurement (baseline or follow-up), 
according to a consensus protocol [10]. Patients were classified into those without MSON 
(nonMSON), unilateral MSON or bilateral MSON. or ‘new MSON’  if an episode occurred 
within the 2 year observation period 
 
Optical Coherence Tomography 
Spectral Domain OCT (SD-OCT, Spectralis, Heidelberg Engineering, Heidelberg, Germany) 
was performed in all subjects at baseline and follow-up as described previously [11]. Scans 
were excluded from the analyses if manual correction for algorithm segmentation failures was 
not possible or if they did not meet the remaining six quality control criteria (OSCAR-IB) 
[12]. This led to a rejection rate of 12.8%. at baseline and 17.8% at 2 year follow up.  
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Statistical analyses 
Data were assessed for normality using the Shapiro-Wilk test followed by graphical 
inspection in SAS (version 9.4). According to distribution non-parametric (Mann Whitney U-
test) or parametric (independent sample T-test) tests were used for comparison of two groups 
or ANOVA and GLM followed by post-hoc analyses for comparison of more than two 
groups. For OCT data all analyses performed on eye-level (two separate eyes per subject) 
were done using generalized estimation equations (GEE), with an exchangeable correlation 
matrix and adjustments for intra-subject inter-eye correlations. Analyses for OCT and visual 
acuity (VA) data averaged from both eyes were done by GLM. Additional adjustments for 
confounding factors such as age, sex and disease type were performed as indicated. The IEPD 
was calculated for the pRNFL and mGCIPL for each patient.  Receiver Operator 
Characteristics (ROC) curves were used to calculate the Area Under the Curve (AUC) to 
describe the level of diagnostic accuracy [13]. The diagnostic value was rated as ‘no or low 
discriminatory power’ for an AUC 0.5-0.7, as of ‘moderate discriminatory power’ for an 
AUC of 0.7-0.9 and of ‘high discriminatory power’ for an AUC >0.9 [14]. The ROC were 
plotted to determine graphically optimised IEPD cut-off values as the shortest distance from 
the top left corner to the ROC curve [15]. p-values of <0.05 were accepted as significant. 
 
RESULTS 
In total 296 subjects were assessed. Of these 26 had to be excluded because a diagnosis of 
previous MSON could not be established with certainty or because of visual symptoms due to 
Uhthoff’s phenomenon or eye movement problems [10]. The overall prevalence of MSON 
was 48.8%. The highest prevalence was found in patients with a secondary progressive (SP) 
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disease course, followed by those with a relapsing remitting (RR) disease course. In patients 
with SP MS a previous episode of MSON was established in the right eye of 11/55 (20.0%), 
in the left eye of 9/55 (16.4%) and bilateral in 13/55 (23.6%). In patients with RR MS a 
previous episode of MSON was established in the right eye of 20/123 (16.3%), in the left eye 
of 21/123 (17.1%) and bilateral in 24/123 (19.5%). Of the patients suffering from primary 
progressive MS 26/29 (89.7%) had no history of MSON, but there was convincing evidence 
for MSON in 3 patients. The baseline data of the patients with and without MSON and HC 
are summarised in Table 1. 
 
[ Table 1 – around here ] 
 
The HC were younger compared to patients without MSON (p=0.0006), but there was no age 
difference between HC, uni- or bilateral MSON (p>0.05). Likewise there was a difference in 
disease duration between groups (p=0.023) which was longer in patients with bilateral MSON 
compared to those without MSON (p=0.008). The VA averaged from both eyes was worse in 
patients with bilateral MSON compared to patients with unilateral MSON (p=0.0006) or 
nonMSON (p=0.024). There was no significant difference between groups for the EDSS 
(Table 1).  
 
Inter-eye percentage differences (IEPD) 
The results of the ROC curves for the IEPD are summarised in Table 2. The AUCs and 
optimised cut-off values are presented for the IEPD of the pRNFL and mGCIPL. For each 
group comparison the optimised IEPD cut-off values were below 10%. The highest AUC 
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(0.94) was found for the mGCIPL for the comparison of patients with bilateral MSON and 
HC with a cut-off as small as 5% inter-eye difference.  
The IEPD of either the pRNFL or mGCIPL was of no diagnostic value for comparing 
unilateral with bilateral MSON. Whilst the IEPD of the mGCIPL did distinguish between HC 
and nonMSON (AUC 0.77) the IEPD of the pRNFL did not (0.56). 
 
[ Table 2 – around here ] 
 
For further illustration the raw data for the IEPD of the pRNFL and mGCIPL are shown in 
Figure 1. The IEPD was highly significantly (p<0.0001) larger in patients with either 
unilateral or bilateral MSON compared to patients with nonMSON or HC. The IEPD for the 
mGCIPL but not the IEPD for the pRNFL was significantly  (p<0.01) higher in patients with 
nonMSON compared to HC. 
 
[ Figure 1 – around here ] 
 
Diagnostic sensitivity and specificity of IEPD 
The diagnostic sensitivity and specificity levels of the IEPD were calculated for those 
comparisons where the AUC indicated a ‘high discriminative power’ (AUC >0.9) [15]. This 
was the IEPD for the mGCIPL comparing patients with unilateral and bilateral MSON to HC 
(see Table 2).  The ROC optimised cut-off value was compared to the consensus cut-off value 
of 20% [10].  
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Using the consensus cut-off value of 20% the diagnostic sensitivity of the IEPD for the 
mGCIPL for unilateral MSON compared to HC was 34% with a specificity of 100%. Using 
the optimised cut-off value of 6% (see Table 2) this changed to a sensitivity level of 70% and 
specificity level of 97%. 
Using the consensus cut-off value of 20% the diagnostic sensitivity of the IEPD for the 
mGCIPL for bilateral MSON compared to HC was 36% with a specificity of 100%. Using the 
optimised cut-off value of 5% (see Table 2) this changed to a sensitivity level of 86% and 
specificity level of 97%. 
 
Validation of IEPD cut-off values 
For validation, sensitivity and specificity levels were re-assessed at follow-up. Two patients 
experienced an episode of MSON between baseline and follow-up and where therefore 
excluded from further analysis. The clinical data at follow-up is summarised in Table 3. The 
drop out of patients was considerable. Overall patients were clinically relatively stable and 
OCT thickness changes within the known physiological variation [16]. 
 
[ Table 3 – around here ] 
 
The diagnostic sensitivity and specificity values for a 6% cut-off for the IEPD of the mGCIPL 
for comparing unilateral MSON with HC were 71% and 97%, respectively.  
The diagnostic sensitivity and specificity values for a 5% cut-off for the IEPD of the mGCIPL 
for comparing bilateral MSON with HC were 83% and 97%, respectively.  
10 
 
The raw data for the IEPD of the pRNFL and mGCIPL at follow-up are shown in Figure 2. 
Interestingly, the two patients who experienced a confirmed episode of MSON between 
baseline and follow-up had a very high IEPD for both retinal layers. But numbers of new 
episodes were too small to allow for a meaningful statistical analysis. 
 
[ Figure 2 – around here ] 
 
DISCUSSION 
This study showed that the IEPD of the pRNFL and the IEPD of the mGCIPL were of 
diagnostic value for MSON. Detailed ROC analyses suggest that the published consensus on a 
20% inter-eye difference for the pRNFL [10] was overly conservative. While inter-eye 
analysis of OCT data is not new (klistorner, Jette),  previous studies have looked at the 
absolute difference between the two eyes and  the 20%  IEPD consensus for the pRNFL is 
based on expert opinion only. There are yet no published data on the inter-eye percentage 
difference for the mGCIPL. The present study suggests that a 5% IEPD of the mGCIPL is of 
excellent diagnostic sensitivity and specificity for bilateral MSON in the setting investigated.  
These findings are relevant because one advantage of the IEPD is that the dimensionless value 
may help to overcome limitations to pool data from different devices and segmentation 
algorithms. As many new OCT devices enter the market adding to heterogeneity between 
center equipment [17], there is a need to start thinking about strategies to facilitate future data 
analyses. The IEPD could potentially be a valuable secondary outcome measure in ON 
treatment trials, pending independent validation.  
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There are statistical advantages to the IEPD, too. As correctly pointed out the statistical 
analyses of OCT data needs to consider inter-eye interactions [18]. Consequently, a concerted 
effort developed OCT reporting guidelines outlining the use of GEE of binocular OCT data 
[19]. The robustness of the model is a strength, but does not lend itself for modelling of 
associations with single outcome variables [11]. Clinical outcome measures such as the 
EDSS, Multiple Sclerosis Functional Composite, cognition, relapse rate and treatment 
response are all relevant [20]. Statistical evaluation of these data makes use of multivariate 
Cox models, Kaplan-Meyer curves, the many flavours of GLM, forms of multimodal 
modelling, principal component analysis and many more [21, 22]  to which the IEPD may 
have advantages over device and eye dependent absolute values of OCT data.  
Finally, the IEPD may overcome present exclusion criteria due to high hypermetropia or 
myopia as well as ethnic retinal layer thickness differences and thickness variations due to 
physiological variability. The observation that the IEPD for the pRNFL and mGCIPL were 
very high in two patients with a new episode of confirmed MSON is encouraging, but will 
require further validation prospectively.  
A likely limitation of the IEPD will be a low diagnostic specificity for separating MSON from 
other forms of ON such as isolated optic neuritis, chronic relapsing isolated optic neuropathy 
(CRION) and neuromyelitis optica ON. None of these patient groups were investigated in the 
present study, which is a limitation of the study. 
Another limitation of the present study is that the IEPD has not been tested in parallel on 
different devices. With the advent of many new OCT devices [17], testing this will be 
resource demanding.  The IEPD is also unlikely to overcome pertinent quality control issues 
[12, 19].   
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There were two unexpected findings in this study. First, the IEPD of the mGCIPL was of high 
diagnostic accuracy for bilateral MSON as well as for the expected unilateral MSON. Second, 
the IEPD of the mGCIPL was superior to the IEPD of the pRNFL. There is a likely 
anatomical explanation for both results. The large variability of the optic disc appearance 
between patients will cause a larger degree of variability of pRNFL data. In contrast, the more 
homogeneous appearance of the macula lutea will make the mGCIPL data more consistent 
between eyes and patients. It is well known that MSON can cause any type of visual field 
defect, the anatomical basis for which is loss of retinal axons and their ganglion cells [2,10]. 
With bilateral MSON the visual field defect frequently is asymmetric between eyes. Therefore 
the diffuse, asymmetric damage caused is likely to affect the IEPD of the mGCIPL 
independent to whether the damage was due to unilateral or bilateral MSON. 
 
CONCLUSION 
This study suggest that the IEPD of the pRNFL and the IEPD of the mGCIPL may prove a 
useful variable for interpretation of OCT data. Advantages of the IEPD are simplicity for 
clinical practise, the possibility to become a cross OCT device measure, the suitability for 
many statistical models on established MS outcome measures and a potentially robust and 
useful secondary outcome measure for treatment trials. There is a need for further validation 
of the IEPD. 
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Fig 1.  Inter-eye percentage difference (IEPD) for the peripapillary retinal nerve fibre layer 
(pRNFL) and macular ganglion cell and inner plexiform layer (mGCIPL) are shown per 
subject and per group at baseline. Levels of significance are indicated as  p<0.0001 (***) 
and p<0.01 (*). HC = healthy controls   
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Fig 2.  Inter-eye percentage difference (IEPD) for the peripapillary retinal nerve fibre layer 
(pRNFL) and macular ganglion cell and inner plexiform layer (mGCIPL) are shown per 
subject and per group at follow-up. Levels of significance are indicated as  p<0.0001 (***) 
and p<0.001 (**), p<0.01 (*). HC = healthy controls   
 
